pre-IPO PHARMA

TAG: Phase 1

Sep 28, 2023

First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors


Sep 26, 2023

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia


Sep 21, 2023

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020


Sep 18, 2023

FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN) May Proceed


Sep 12, 2023

Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors



Sep 12, 2023

Anokion Announces Clinical Progress with KAN-101 and ANK-700


Sep 11, 2023

Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress


Sep 7, 2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3


Aug 24, 2023

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme


Aug 22, 2023

Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor



Aug 17, 2023

Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS


Aug 15, 2023

Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)


Aug 3, 2023

Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease


Aug 3, 2023

Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions


Aug 1, 2023

Pipeline Therapeutics Announces First Subject Dosed with PIPE-791 in Phase 1 Study



Jul 27, 2023

Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies


Jul 24, 2023

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours


Jul 18, 2023

Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients


Jul 11, 2023

IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042


Jul 11, 2023

Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism USA - English APAC - English



Jul 5, 2023

Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair (omalizumab)


Jun 30, 2023

Toragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer


Jun 23, 2023

Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions


Jun 20, 2023

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies


Jun 20, 2023

Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders



Jun 15, 2023

Anokion Announces Publication in The Lancet Gastroenterology and Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial


Jun 8, 2023

Inversago Pharma to Present Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions


Jun 8, 2023

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1 Study of PIPE-791


Jun 7, 2023

Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023


Jun 5, 2023

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET Dose Escalation Results at ASCO 2023 Annual Meeting USA - English USA - Français USA - English USA - Français



Jun 5, 2023

Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly


Jun 5, 2023

Amolyt Pharma lance l'essai clinique de phase 1 de l’AZP-3813, peptide antagoniste du récepteur de l'hormone de croissance pour le traitement de l'acromégalie


Jun 5, 2023

Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases


Jun 5, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)


Jun 3, 2023

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting



Jun 2, 2023

Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting USA - English USA - Français


Jun 1, 2023

ReAlta Life Sciences Announces Proof of Mechanism Data from the Phase 1b Inhaled LPS Trial of RLS-0071, Demonstrating Powerful Inhibition of Lung Neutrophils and Inflammatory Cytokines


May 31, 2023

Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis


May 25, 2023

AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting


May 22, 2023

HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting



May 22, 2023

Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin's Lymphoma


May 20, 2023

Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress


May 16, 2023

Cerevance Announces Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)


May 16, 2023

Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas


May 15, 2023

Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program



May 9, 2023

Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease


May 2, 2023

Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors


May 1, 2023

Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO


Apr 27, 2023

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine USA - English APAC - English


Apr 25, 2023

Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome



Apr 20, 2023

Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate


Apr 18, 2023

Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial


Apr 18, 2023

Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor


Apr 18, 2023

Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023


Apr 14, 2023

MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting



Apr 14, 2023

Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023


Apr 12, 2023

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma


Apr 11, 2023

K36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multiple myeloma and addition of Mr. Michael Heffernan as Independent Board Director


Mar 30, 2023

CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference


Mar 30, 2023

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis



Mar 28, 2023

Direct Biologics Announces First Patient Dosed with ExoFlo™ in a Phase 1 Clinical Trial for Medically Refractory Ulcerative Colitis


Mar 28, 2023

Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates


Mar 23, 2023

GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders


Mar 23, 2023

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile


Mar 21, 2023

Direct Biologics Announces Initiation of Phase 1 Clinical Trial for Medically Refractory Crohn’s Disease



Mar 20, 2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas


Mar 20, 2023

RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors


Mar 16, 2023

Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate


Mar 15, 2023

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia


Mar 14, 2023

Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors



Mar 14, 2023

Immune-Onc Therapeutics Announces IO-108 Phase I Clinical Trial Results Selected for Oral Presentation at AACR Annual Meeting 2023


Mar 9, 2023

Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis


Mar 7, 2023

Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001


Mar 7, 2023

Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies


Mar 1, 2023

Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors



Mar 1, 2023

Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers


Feb 27, 2023

Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody ES014


Feb 27, 2023

Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease


Feb 23, 2023

Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress


Feb 23, 2023

Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer



Feb 23, 2023

Bexion Pharmaceuticals, Inc. Announces Publication of Pediatric Phase 1 (KOURAGE) Results


Feb 16, 2023

Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease at the WORLDSymposium 2023


Feb 14, 2023

enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium


Feb 7, 2023

Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson's Disease


Feb 6, 2023

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent



Feb 3, 2023

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies


Jan 31, 2023

Arugula Sciences announces FDA Approval to Proceed with Phase 1 Study of SIG002, a Perinatal-derived Secretome Product, for the Treatment of Big Toe Osteoarthritis (Hallux Rigidus)


Jan 30, 2023

Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders


Jan 17, 2023

Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors


Jan 10, 2023

Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target



Jan 9, 2023

Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia


Jan 5, 2023

ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer


Jan 5, 2023

QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS


Jan 5, 2023

NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes


Jan 5, 2023

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics



Jan 4, 2023

Arugula Sciences Announces Company Launch with FDA Phase 1 Approval for Osteoarthritis Therapy


Dec 21, 2022

Osmol Therapeutics Provides Corporate Update at BIOTECH SHOWCASE 2023


Dec 21, 2022

Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023


Dec 15, 2022

Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease


Dec 15, 2022

AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib in Glioma



Dec 14, 2022

BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans


Dec 12, 2022

Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting


Dec 12, 2022

Orca Bio Presents Encouraging Interim Clinical Data on Orca-Q in Haploidentical Allogeneic Hematopoietic Stem Cell Transplants at 64th ASH Annual Meeting


Dec 11, 2022

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting


Dec 10, 2022

Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)



Dec 9, 2022

Dragonfly Therapeutics annonce qu'un premier patient a reçu une dose de TriNKET ciblant l'EGFR dans le cadre de son étude de phase 1 France - Français USA - English USA - English USA - English USA - English España - español España - español Deutschland - Deutsch Deutschland - Deutsch


Dec 8, 2022

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET USA - English USA - English


Dec 8, 2022

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice


Dec 8, 2022

Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium


Dec 8, 2022

Federation Bio Administers First Dose in Phase 1 Clinical Trial Evaluating Investigational Bacterial Cell Therapy



Dec 8, 2022

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET USA - English USA - English USA - español USA - Deutsch USA - Français


Dec 7, 2022

KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, a First-In-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors


Dec 7, 2022

Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis


Dec 5, 2022

BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest


Nov 30, 2022

Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors USA - English USA - English



Nov 30, 2022

Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors


Nov 29, 2022

Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder


Nov 23, 2022

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study


Nov 17, 2022

ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer


Nov 15, 2022

ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial



Nov 10, 2022

Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting


Nov 10, 2022

IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022


Nov 10, 2022

Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies


Oct 31, 2022

Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, a Novel Therapeutic for Amyotrophic Lateral Sclerosis


Oct 31, 2022

Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors



Oct 26, 2022

Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy


Oct 21, 2022

Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium


Oct 19, 2022

Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic


Oct 19, 2022

OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease


Oct 17, 2022

Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Products Targeting Antibiotic-Resistant Bacterial Infections at 2022 ID Week Meeting



Oct 17, 2022

Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate


Oct 9, 2022

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes


Oct 3, 2022

Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Study of Zelpultide Alfa (AT-100) in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD) USA - English España - español Deutschland - Deutsch France - Français USA - English


Oct 3, 2022

Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Study of Zelpultide Alfa (AT-100) in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD) USA - English USA - español USA - Deutsch USA - Français USA - English


Sep 27, 2022

Karolinska Development’s portfolio company Modus Therapeutics has completed recruitment in a clinical phase 1b study of sevuparin



Sep 21, 2022

NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249


Sep 10, 2022

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination


Sep 8, 2022

Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression


Sep 7, 2022

Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction


Sep 4, 2022

Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022



Sep 4, 2022

CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress


Sep 2, 2022

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria


Aug 29, 2022

AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate


Aug 23, 2022

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors


Aug 17, 2022

Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)



Aug 2, 2022

Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma


Jul 26, 2022

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre


Jul 20, 2022

Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of Autoimmune and Inflammatory Diseases


Jul 14, 2022

Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update


Jul 13, 2022

Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide



Jul 13, 2022

Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia


Jul 6, 2022

Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors


Jul 5, 2022

ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations


Jun 28, 2022

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer


Jun 22, 2022

FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults



Jun 22, 2022

Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy


Jun 15, 2022

Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184, a Novel NEK7/NLRP3 Inhibitor


Jun 14, 2022

Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine


Jun 13, 2022

Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia


Jun 10, 2022

Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress



Jun 7, 2022

Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy


Jun 7, 2022

Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting


Jun 6, 2022

Nouscom Announces Positive Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022


Jun 3, 2022

Sapience Therapeutics Presents Phase 1 Data at ASCO 2022 Including Efficacy Proof-of-Concept with ST101 in Patients with Refractory Solid Tumors


Jun 2, 2022

Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168



Jun 1, 2022

Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting


Jun 1, 2022

Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved


Jun 1, 2022

ReAlta Life Sciences, Inc. Doses First Patient in Phase 1b Inhaled-LPS Challenge Clinical Trial to Support Development of RLS-0071 in Severe Asthma


May 31, 2022

Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82nd Scientific Sessions and Endocrine Society’s Annual Meeting, ENDO 2022


May 31, 2022

Memo Therapeutics AG Initiates Phase 1 Clinical Study of MTX-005 Against BK Virus Infection



May 30, 2022

AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease


May 27, 2022

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022


May 26, 2022

Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting


May 26, 2022

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


May 25, 2022

Codagenix Initiates Phase 1 Evaluation of Intranasal Vaccine CoviLiv™ for Use as COVID-19 Booster



May 24, 2022

PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting


May 23, 2022

Anokion Announces Positive Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022


May 23, 2022

Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial USA - English USA - English


May 23, 2022

Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer


May 23, 2022

Starton Therapeutics Announces Approval to Proceed with Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD



May 23, 2022

Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial


May 19, 2022

Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting


May 18, 2022

XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT


May 17, 2022

HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2


May 17, 2022

Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene and Cell Therapy 25th Annual Meeting



May 16, 2022

Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress


May 16, 2022

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference


May 4, 2022

Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation


May 3, 2022

Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells


May 2, 2022

Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous anti-VEGF wet AMD and DME Candidate at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting



Apr 27, 2022

Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


Apr 25, 2022

Starton Therapeutics Doses First Subjects in Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide


Apr 21, 2022

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer


Apr 21, 2022

Adiso Therapeutics Announces Completion of Enrollment in a Phase 1b Study of ADS024 for the Prevention of C. difficile Recurrence


Apr 19, 2022

BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications



Apr 19, 2022

AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2022


Apr 13, 2022

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)


Apr 13, 2022

PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host and Microbe and Highlights Planned Presentations of Phase 2 VE303 Results


Apr 13, 2022

Adiso Therapeutics Announces Completion of First Cohort Enrollment in a Phase 1b Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis


Apr 13, 2022

Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host and Microbe and Highlights Planned Presentations of Phase 2 VE303 Results



Apr 12, 2022

Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors


Apr 12, 2022

Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer


Apr 11, 2022

APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial


Apr 11, 2022

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022


Apr 11, 2022

Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting



Apr 11, 2022

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways


Apr 8, 2022

Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022


Apr 8, 2022

Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN004, a Novel 5T4-Antibody-Drug-Conjugate


Apr 8, 2022

Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Apr 8, 2022

Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2022 American Association for Cancer Research (AACR) Annual Meeting



Apr 5, 2022

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation


Apr 5, 2022

Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors


Apr 4, 2022

ReAlta Life Sciences’ RLS-0071 Demonstrates Excellent Safety Profile and Confirmed Target Engagement in First-in-Human Phase 1 Clinical Trial


Apr 1, 2022

Airway Therapeutics annonce la première dose administrée au patient dans l'essai de phase 1b de l'AT-100 chez les nourrissons prématurés à risque de dysplasie bronchopulmonaire (DBP) France - Français France - Français USA - English USA - English USA - English USA - English España - español España - español Deutschland - Deutsch Deutschland - Deutsch Latin America - español Brazil - Português


Apr 1, 2022

Airway Therapeutics annonce la première dose administrée au patient dans l'essai de phase 1b de l'AT-100 chez les nourrissons prématurés à risque de dysplasie bronchopulmonaire (DBP) Israel - Français USA - English Israel - English USA - español USA - Deutsch Latin America - español Brazil - Português



Mar 31, 2022

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD) USA - English USA - English USA - English USA - English


Mar 31, 2022

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)


Mar 31, 2022

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD) USA - English Israel - English USA - español USA - Deutsch Latin America - español Brazil - Português


Mar 30, 2022

Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies


Mar 30, 2022

Accutar Biotechnology Announces First Patient Dosed with AC0176 in Phase 1 Study in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)



Mar 28, 2022

Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting


Mar 25, 2022

Nimbus Therapeutics Presents Clinical Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD Annual Meeting


Mar 24, 2022

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference


Mar 24, 2022

Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022


Mar 24, 2022

STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder



Mar 22, 2022

KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 22, 2022

Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis


Mar 21, 2022

Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers


Mar 17, 2022


Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting



Mar 17, 2022

Codagenix Intranasal COVID-19 Vaccine Shows Potent Cellular Immune Response Against Conserved Viral Proteins, Indicating Potential for Immunogenicity Against Omicron and Future Variants in Phase 1 Data


Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC™ Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 15, 2022

Inversago Pharma Announces Dosing of First Participant With Metabolic Syndrome in Phase 1B Clinical Trial


Mar 10, 2022

Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis


Mar 10, 2022

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain



Mar 9, 2022

Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors


Mar 8, 2022

Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314


Mar 8, 2022

Digestome Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of DGX-001


Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English USA - English


Mar 7, 2022

Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases



Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English Israel - English


Mar 2, 2022

Dragonfly Therapeutics annonce la réalisation de l'étape de développement clinique de phase 1 pour le programme d'immunothérapie expérimentale IL-12 en collaboration avec Bristol Myers Squibb France - Français USA - English Deutschland - Deutsch España - español


Mar 1, 2022

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb


Mar 1, 2022

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers


Mar 1, 2022

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio



Mar 1, 2022

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion


Mar 1, 2022

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb USA - English USA - Deutsch USA - español USA - Français


Feb 23, 2022

Jnana Therapeutics to Advance JNT-517 as Development Candidate and Potential First-in-Class Oral Treatment for PKU


Feb 22, 2022

Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma


Feb 17, 2022

Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease



Feb 17, 2022

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers USA - English USA - English


Feb 17, 2022

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers


Feb 16, 2022

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies


Feb 16, 2022

Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation


Feb 14, 2022

Primmune Therapeutics Presents Interim Analysis of Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)



Feb 10, 2022

Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease


Feb 10, 2022

AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole


Feb 8, 2022

Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy


Feb 7, 2022

Primmune Therapeutics to Present Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)


Feb 7, 2022

Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer



Feb 3, 2022

Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors


Feb 2, 2022

NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease


Feb 2, 2022

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)


Jan 31, 2022

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors


Jan 26, 2022

BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188



Jan 25, 2022

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766


Jan 17, 2022

Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update


Jan 12, 2022

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis


Jan 12, 2022

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer


Jan 10, 2022

Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide



Jan 6, 2022

Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor Program and Provides Additional Business Updates


Jan 6, 2022

Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs


Jan 5, 2022

Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook


Jan 5, 2022

Samus Therapeutics Announces First Patient Dosed in Phase 1b Study of Icapamespib in Recurrent Malignant Glioma


Dec 24, 2021

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer



Dec 23, 2021

Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection


Dec 14, 2021

OnKure Therapeutics Announces Positive Topline First-in-Human Phase 1 Results for OKI-179


Dec 13, 2021

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition


Dec 11, 2021

Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)


Dec 9, 2021

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer



Dec 8, 2021

Tranquis Therapeutics Announces Initiation of Phase 1 Study of TQS-168


Dec 8, 2021

Shasqi Awarded a Second NCI Grant of $1.9M to Accelerate the Development of SQ3370


Dec 6, 2021

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies


Dec 1, 2021

Karolinska Development’s portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin


Dec 1, 2021

National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer



Dec 1, 2021

Accutar Biotechnology Announces First Patient Dosed with AC0682 in Phase 1 Study in Patients with ER-Positive / HER2-Negative Locally Advanced or Metastatic Breast Cancer


Nov 30, 2021

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis


Nov 22, 2021

NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting


Nov 17, 2021

First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology


Nov 15, 2021

Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis



Nov 10, 2021

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine for the treatment of MSI-H solid tumors


Nov 9, 2021

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease


Nov 5, 2021

Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells


Nov 4, 2021

Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed and Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition


Nov 4, 2021

NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study



Nov 4, 2021

Shasqi to Present Data Updates at Upcoming SITC and CTOS Meetings


Nov 3, 2021

Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168 for the Treatment of ALS at Neuroscience 2021 Annual Meeting


Nov 2, 2021

BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies


Nov 2, 2021

Antiva Biosciences Closes $31 Million Series D Equity Financing


Nov 2, 2021

OncoResponse Announces Initiation of Phase 1 Trial of OR2805 - Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy - in Patients with Advanced Cancer



Nov 2, 2021

Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™


Nov 1, 2021

Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardio-Metabolic Diseases


Oct 28, 2021

HUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated Tumors


Oct 23, 2021

OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress


Oct 21, 2021

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients



Oct 19, 2021

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia


Oct 18, 2021

Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis


Oct 13, 2021

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors


Oct 13, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma


Oct 6, 2021

PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer



Oct 6, 2021

Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients with Relapsed or Refractory Malignancies


Oct 6, 2021

Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress


Oct 4, 2021

Enteris BioPharma Announces Successful Completion of Phase 1 Clinical Trial of Optimized Peptelligence Oral Leuprolide


Oct 4, 2021

Appello Pharmaceuticals Begins Phase 1 Clinical Trial


Oct 1, 2021

Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting



Oct 1, 2021

Amolyt Pharma présente les résultats positifs de son étude clinique de phase 1 de l’AZP-3601 au congrès annuel 2021 de l’American Society for Bone and Mineral Research


Sep 29, 2021

Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021


Sep 29, 2021

EpicentRx Announces Completion of First Cohort in Phase 1 "BETA PRIME" Trial with AdAPT-001


Sep 29, 2021

Codagenix Presents Positive Phase 1 Data for COVI-VAC Intranasal COVID-19 Vaccine at IDWeek 2021


Sep 22, 2021

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies



Sep 21, 2021

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting


Sep 21, 2021

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0682 in ER-Positive Breast Cancer


Sep 16, 2021

Nouscom announces initial results from Phase 1 trial for NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine, in MSI-H solid tumors


Sep 16, 2021

Shasqi Presents Initial Data Validating Approach of Click Chemistry Activated Oncology Therapeutics at ESMO Congress 2021


Sep 16, 2021

Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021



Sep 15, 2021

Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients


Sep 14, 2021

KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors


Sep 13, 2021

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors


Sep 13, 2021

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors USA - English Brazil - Português


Sep 9, 2021

Calypso Biotech Announces First Patient With Celiac Disease Dosed in anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1b Trial, and Extension of Series A to €28M



Sep 7, 2021

Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker


Sep 2, 2021

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers USA - English USA - English


Sep 2, 2021

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers


Sep 1, 2021

Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal Cancer


Sep 1, 2021

Lumen Bioscience Launches Phase 1 Trial of Oral Biologic Drug for Preventing C. difficile Infection Recurrence



Aug 27, 2021

Airway Therapeutics annonce avoir administré une dose à son premier patient dans le cadre de l'essai de phase 1b de l'AT-100 chez les patients atteints de COVID-19 sévère France - Français USA - English España - español Deutschland - Deutsch


Aug 26, 2021

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients USA - English España - español France - Français Deutschland - Deutsch


Aug 25, 2021

Camino Pharma initiates Phase 1 study of SBP-9330 in development for the treatment of tobacco use disorder


Aug 25, 2021

Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613 (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer


Aug 24, 2021

Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer



Aug 24, 2021

BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine


Aug 12, 2021

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors


Aug 11, 2021

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19


Aug 11, 2021

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant


Aug 4, 2021

PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia; Announces Appointment of Chief Medical Officer; Establishes Clinical Advisory Board



Aug 3, 2021

Engrail Therapeutics Extends Series A Financing to $64 Million


Aug 2, 2021

Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers


Jul 29, 2021

Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101


Jul 28, 2021

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145


Jul 28, 2021

Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation



Jul 27, 2021

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina


Jul 27, 2021

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments


Jul 26, 2021

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection


Jul 22, 2021

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent


Jul 21, 2021

IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes



Jul 14, 2021

Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus


Jul 14, 2021

Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506


Jul 13, 2021

Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158


Jul 12, 2021

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma


Jul 9, 2021

Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults



Jul 7, 2021

Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b / 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers


Jul 6, 2021

Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment


Jul 2, 2021

Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)


Jun 30, 2021

PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease


Jun 29, 2021

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)



Jun 29, 2021

Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia


Jun 29, 2021

IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial


Jun 28, 2021

MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy


Jun 28, 2021

Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection


Jun 24, 2021

Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer



Jun 24, 2021

Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension


Jun 23, 2021

Strand Therapeutics Raises $52M in Oversubscribed Series A Round


Jun 17, 2021

Pinteon Therapeutics Announces $3 Million Award from Advanced Technology International to Support Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury


Jun 17, 2021

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial


Jun 17, 2021

Qpex Biopharma Initiates Phase 1 Study of QPX9003 Targeting Antibiotic-Resistant Pathogens



Jun 10, 2021

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes


Jun 10, 2021

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes


Jun 9, 2021

BioTheryX Announces First Patient Dosed with BTX-A51 in Phase 1 Clinical Trial in Patients with Advanced Solid Tumors


Jun 8, 2021

BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease


Jun 7, 2021

IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial with Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme



Jun 7, 2021

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting


Jun 4, 2021

Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting


Jun 4, 2021

Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting


Jun 4, 2021

Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting


Jun 4, 2021

Ichnos Sciences Presents Preclinical Data Confirming Potential For ISB 1342 In Relapsed/Refractory Multiple Myeloma At 2021 ASCO Annual Meeting



Jun 2, 2021

BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Patients at 2021 American Society of Clinical Oncology (ASCO) Meeting


Jun 1, 2021

Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting


May 27, 2021

AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology


May 26, 2021

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01


May 20, 2021

Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours



May 20, 2021

BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology


May 20, 2021

Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting


May 20, 2021

IN8bio Presents First Cohort Phase 1 Clinical Data on INB-200 at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting


May 19, 2021

Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting


May 19, 2021

Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation



May 19, 2021

Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment


May 18, 2021

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences


May 18, 2021

ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071 to Include Three Multiple-Ascending Dose Cohorts and An Additional Single Ascending Dose Cohort


May 17, 2021

Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope, at the American College of Cardiology 70th Annual Scientific Session and Expo


May 14, 2021

Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma



May 13, 2021

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)


May 13, 2021

Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial


May 12, 2021

Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections


May 6, 2021

Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001 in Patients with Acute Traumatic Brain Injury


May 6, 2021

Lyndra Therapeutics Receives FDA Clearance of Investigational New Drug Application for LYN-014, its Once-Weekly Oral Levomethadone Treatment in Development for Opioid Use Disorder



May 5, 2021

Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19


May 5, 2021

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis


May 4, 2021

Revolo Biotherapeutics Announces Positive Data from Additional Phase 1 Clinical Trial of ‘1104, its Peptide Drug for Allergic Disease


May 1, 2021

Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial


Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery USA - English USA - English



Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery


Apr 26, 2021

Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor USA - English USA - English


Apr 26, 2021

Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor


Apr 22, 2021

Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo (nivolumab) for the Treatment of High-Grade Gliomas


Apr 21, 2021

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma



Apr 20, 2021

SiteOne Therapeutics Announces Initiation of Phase 1 Clinical Trial for its Non-Opioid Analgesic for Acute Pain


Apr 19, 2021

ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials


Apr 15, 2021

Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration


Apr 14, 2021

BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen’s Phase 1 APJ Agonist To Treat Diseases of Aging


Apr 13, 2021

Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy



Apr 12, 2021

Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma


Apr 6, 2021

UNION therapeutics' COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication


Apr 6, 2021

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021


Mar 31, 2021

OncoResponse Raises $40.6 Million Series C Financing


Mar 25, 2021

Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)



Mar 23, 2021

Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis


Mar 22, 2021

Starton Therapeutics Completes Pre-IND Meeting with FDA: Clearing Path to Phase 1 Clinical Study for STAR-LLD Continuous Infusion


Mar 17, 2021

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis


Mar 16, 2021

Anokion Announces Initiation of Multiple-Ascending Dose Portion of its Phase 1 Clinical Trial with KAN-101 for the Treatment of Celiac Disease


Mar 16, 2021

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program



Mar 16, 2021

Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021


Mar 15, 2021

CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease


Mar 11, 2021

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy


Mar 10, 2021

Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study


Mar 10, 2021

Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma



Mar 10, 2021

Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate


Mar 6, 2021

Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections


Mar 3, 2021

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies


Mar 3, 2021

Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data


Mar 3, 2021

Ridgeback Biotherapeutics Announces Publication of Phase 1 Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Molnupiravir in Healthy Volunteers



Mar 2, 2021

Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307


Mar 1, 2021

CARISMA Therapeutics Completes Series B Financing Totaling $59 Million


Feb 25, 2021

AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19


Feb 24, 2021

Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy


Feb 16, 2021

Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19



Feb 16, 2021

ReAlta Life Sciences Doses First Subject in Phase 1 Healthy Volunteers Study of RLS-0071


Feb 8, 2021

Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation


Feb 2, 2021

LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102


Feb 2, 2021

Selva Therapeutics Announces Successful Completion of Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19


Feb 1, 2021

Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001



Feb 1, 2021

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet


Feb 1, 2021

SIFI gibt die Veröffentlichung der Phase 1 seiner Studie über Polihexanid in dem British Journal of Ophthalmology bekannt Deutschland - Deutsch France - Français USA - English España - español


Jan 27, 2021

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema


Jan 25, 2021

Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection


Jan 21, 2021

Lyndra Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Once-Weekly Rosuvastatin Extended-Release Capsule, LYN-047



Jan 20, 2021

TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF


Jan 13, 2021

Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas


Jan 12, 2021

Enteris BioPharma to Host Webinar on Strategies for Initiating Phase 1 Clinical Development with Limited API


Jan 11, 2021

Codagenix and Serum Institute of India Initiate Dosing in Phase 1 Trial of COVI-VAC, a Single Dose, Intranasal, Live Attenuated Vaccine for COVID-19


Dec 16, 2020

Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564



Dec 15, 2020

Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain


Dec 10, 2020

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium


Dec 10, 2020

STALICLA Translates its Novel Precision Medicine Approach for Autism Spectrum Disorder into Clinical Development with First Patient in Phase 1b Trial of STP1


Dec 8, 2020

Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study


Dec 7, 2020

Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID Undergoing Hematopoietic Cell Transplantation



Dec 7, 2020

ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma


Dec 7, 2020

Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma


Dec 6, 2020

ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting


Dec 4, 2020

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates


Dec 3, 2020

IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product candidate, at ASH 2020



Dec 3, 2020

Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections


Dec 2, 2020

Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application


Dec 2, 2020

Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis


Dec 1, 2020

Codagenix Inc. Completes Dosing for Phase 1 Trial of Live-Attenuated, Intranasal Vaccine for Respiratory Syncytial Virus (RSV)


Dec 1, 2020

Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020



Nov 30, 2020

NeoImmuneTech Announces First Patient Dosed in Phase 1 Study of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19


Nov 23, 2020

Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma


Nov 19, 2020

NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline


Nov 19, 2020

Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study


Nov 18, 2020

PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314



Nov 13, 2020

Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study


Nov 13, 2020

BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations


Nov 12, 2020

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic


Nov 12, 2020

Selva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19


Nov 12, 2020

CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO (nivolumab) in Muscle-Invasive Bladder Cancer



Nov 11, 2020

Medicago Announces Positive Phase 1 Results for Its COVID-19 Vaccine Candidate


Nov 10, 2020

ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study


Nov 9, 2020

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting


Nov 9, 2020

7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines


Oct 30, 2020

Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B



Oct 29, 2020

AnHeart Announces Publication of Pooled Analysis of two Phase 1 Studies of Taletrectinib in ROS1+ NSCLC


Oct 29, 2020

IM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a Study


Oct 29, 2020

Mebias Discovery Receives Grant from NIDA to Advance MEB-1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder


Oct 26, 2020

Rain Therapeutics Announces a Phase 1 Trial Update for the MDM2 Inhibitor, RAIN-32, at the 32nd EORTC-NCI-AACR Virtual Symposium


Oct 22, 2020

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases



Oct 21, 2020

ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2


Oct 21, 2020

Affinivax Announces the Presentation of Phase 1 Clinical Data for its MAPS™ Vaccine for Streptococcus pneumoniae at IDWeek 2020


Oct 20, 2020

A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613️ (devimistat) for Patients With Pancreatic Cancer in Japan


Oct 20, 2020

Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19


Oct 15, 2020

FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity



Oct 14, 2020

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism


Oct 14, 2020

Amolyt Pharma annonce la première administration d’AZP-3601, analogue de la parathormone en développement dans l’hypoparathyroidie, dans son essai clinique de phase 1


Oct 13, 2020

Goldfinch Bio Announces Upcoming Presentation of Phase 1 Clinical Data for Lead Precision Kidney Therapeutic Candidate, GFB-887, and Expansion of Scientific Leadership Team


Oct 12, 2020

Vedanta Biosciences Announces Additional Pharmacokinetics Data From Phase 1 Study of VE202 for Inflammatory Bowel Disease to Be Presented at United European Gastroenterology Week 2020


Oct 12, 2020

Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine



Oct 8, 2020

Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid


Oct 5, 2020

Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors


Sep 30, 2020

Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies


Sep 29, 2020

Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker


Sep 28, 2020

COVISTAT, a Subsidiary of Ensysce Biosciences Inc, a California Based Company With a Mission to Solve the Opioid Crisis, Is Commencing Phase 1 Study of Novel COVID-19 Treatment



Sep 25, 2020

Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate


Sep 24, 2020

Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis


Sep 22, 2020

Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate


Sep 22, 2020

Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myelodysplastic Syndromes/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation


Sep 21, 2020

Bristol Myers Squibb Completes Acquisition of Forbius



Sep 18, 2020

Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors


Sep 17, 2020

Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea


Sep 15, 2020

Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase 1 Clinical Data Presented Recently at Several Scientific Conferences


Sep 15, 2020

CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease


Sep 14, 2020

LB Pharmaceuticals Inc Announces Results of LB-102 Phase 1 First-in-Human Clinical Study



Sep 10, 2020

Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration


Sep 1, 2020

Nocion Therapeutics Advances to Clinical Stage and Expands Leadership


Aug 27, 2020

Treadwell Announces Initiation of Expansion Cohorts in Ongoing Phase 1 Study of Oral TTK Inhibitor, CFI-402257, in Patients with Breast Cancer and Additional Solid Tumors


Aug 27, 2020

Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress™ 2020


Aug 26, 2020

Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050



Aug 24, 2020

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio


Aug 24, 2020

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma


Aug 24, 2020

Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA (pembrolizumab) for Advanced Solid Tumors


Aug 24, 2020

Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA (pembrolizumab) for Advanced Solid Tumors USA - English Israel - English


Aug 21, 2020

SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19



Aug 20, 2020

Terns Pharmaceuticals to Present Data on Multiple NASH Programs at The Digital International Liver Congress™ 2020


Aug 18, 2020

Aligos Therapeutics Doses First Subject in Phase 1 Proof of Concept Study of Oligonucleotide Drug Candidate ALG-010133


Aug 17, 2020

Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002


Aug 13, 2020

MicuRx Announces CARB-X US$7.78 Million Funding for Development of MRX-8


Aug 12, 2020

Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy



Aug 12, 2020

Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506


Aug 11, 2020

SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19


Aug 11, 2020

FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program


Aug 10, 2020

Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes


Jul 30, 2020

Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH



Jul 30, 2020

SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-176 for Seasonal Influenza


Jul 29, 2020

Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company's Platform for Treating Neurodegenerative Diseases


Jul 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy


Jul 27, 2020

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia


Jul 16, 2020

Oncorus Initiates First-in-Human Phase 1 Study of ONCR-177 for the Treatment of Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors



Jul 16, 2020

Imvax Inc. Raises $112 Million in Series C Financing


Jul 14, 2020

Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease


Jul 14, 2020

Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant


Jun 30, 2020

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults USA - English USA - English


Jun 30, 2020

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults USA - English India - English



Jun 26, 2020

AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research


Jun 24, 2020

IM Therapeutics Announces First Patient Dosed in Phase 1 Study of Its Lead Drug IMT-002 for Type 1 Diabetes


Jun 24, 2020

Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients


Jun 22, 2020

RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting


Jun 22, 2020

Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model



Jun 19, 2020

Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate


Jun 19, 2020

Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19


Jun 16, 2020

Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform


Jun 15, 2020

Arecor announces Phase 1 of AT247 at ADA


Jun 12, 2020

Forma Therapeutics Presents Safety, Pharmacokinetic and Pharmacodynamic Data from Phase 1 Clinical Trial for Investigational Agent FT-4202 in Patients with Sickle Cell Disease



Jun 12, 2020

ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma


Jun 11, 2020

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease


Jun 10, 2020

Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation


Jun 9, 2020

Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)


Jun 9, 2020

Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis



Jun 2, 2020

Cellenkos Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded, Randomized, Placebo-Controlled Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells (CK0802) for Treatment of COVID-19 Associated Acute Respiratory Distress Syndrome USA - English USA - English


Jun 2, 2020

First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma


Jun 1, 2020

BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting


May 29, 2020

RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial


May 29, 2020

ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors



May 29, 2020

Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance


May 27, 2020

Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies


May 26, 2020

Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613 (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program


May 18, 2020

ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25th Congress of the European Hematology Association (EHA)


May 15, 2020

Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI



May 14, 2020

ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting


May 13, 2020

Tarveda Therapeutics Reports Complete Data from Phase 1 Portion of Phase 1/2a Study of PEN-866 to be Presented at the ASCO20 Virtual Scientific Program


May 12, 2020

Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation


Apr 27, 2020

Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I


Apr 2, 2020

Dynacure Announces €50M ($55M) Series C Financing



Mar 30, 2020

Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137


Mar 26, 2020

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress


Mar 26, 2020

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress English English English


Mar 26, 2020

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress USA - English Israel - English


Mar 12, 2020

Arcellx Announces FDA Orphan Drug Designation for CART-ddBCMA for the Treatment of Multiple Myeloma



Mar 6, 2020

Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH


Mar 5, 2020

Dynacure Announces First Patient Dosed in Phase 1 / 2 'UNITE-CNM' Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)


Feb 28, 2020

Arcellx Announces First Patient Treated with T Cell Therapy Utilizing the Company’s Novel Binding Domain


Feb 27, 2020

Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy


Feb 27, 2020

Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease



Feb 21, 2020

Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody


Feb 19, 2020

Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH


Feb 10, 2020

Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in the Treatment of GI Cancers


Feb 4, 2020

AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure


Jan 30, 2020

Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder



Jan 30, 2020

SQZ Biotech Announces First Patient Dosed in Phase 1 Trial of SQZ-PBMC-HPV for HPV+ Tumors


Jan 22, 2020

LB Pharmaceuticals Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of LB-102, a Novel Benzamide for the Treatment of Schizophrenia


Jan 21, 2020

Anokion Announces FDA Clearance of IND Application for its Lead Program in Celiac Disease


Jan 16, 2020

BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Multi-Kinase Inhibitor


Jan 15, 2020

Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1



Jan 10, 2020

Terns Pharmaceuticals Presents Results From An Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH


Jan 9, 2020

Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration


Jan 7, 2020

CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study


Jan 6, 2020

ESCAPE Bio Announces Excellent Safety and Tolerability in Phase 1 Study of Oral S1P5 Receptor Agonist ESB1609


Dec 20, 2019

Longeveron LLC Announces Completion of Enrollment in Phase 1 Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Alzheimer's Disease



Dec 18, 2019

Eleusis Announces Phase 1 Trial Results of Lysergic Acid Diethylamide (LSD) in Healthy Older Volunteers, Potential to Evaluate as Disease Modifying Therapy for Alzheimer’s Disease


Dec 18, 2019

Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia


Dec 9, 2019

Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors


Dec 9, 2019

Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting


Dec 9, 2019

Amphivena Reports Data on Phase 1 Study of AMV564 at Ash Annual Meeting



Dec 9, 2019

Jasper Therapeutics Announces Upcoming Data Presentation on Lead Program, JSP191, at 61st American Society of Hematology (ASH) Annual Meeting and Exposition


Dec 8, 2019

Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy


Dec 8, 2019

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting


Dec 6, 2019

Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to Transform Curative Hematopoietic Cell Transplants


Dec 5, 2019

Meissa Vaccines Receives FDA Clearance of IND Application for a Phase 1 Clinical Trial of MV-012-968 for Respiratory Syncytial Virus



Dec 5, 2019

Samus Therapeutics Announces Presentation of PU-AD Phase 1 Data for Alzheimer's Disease at CTAD Congress


Dec 4, 2019

ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superagonist in Non-Muscle Invasive Bladder Cancer


Dec 4, 2019

Adastra Pharmaceuticals Announces FDA and EMA Orphan Drug Designation Has Been Granted for Zotiraciclib in the Treatment of Glioma


Dec 3, 2019

Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth


Nov 25, 2019

Cerevel Therapeutics to Present Safety, Tolerability, and Pharmacokinetics Results From Phase 1 Trial of CVL-865



Nov 25, 2019

EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma


Nov 20, 2019

Athira Pharma to Present Phase 1 Data for NDX-1017 in Oral Presentation at 2019 Clinical Trials on Alzheimer's Disease (CTAD) Conference


Nov 14, 2019

ALX Oncology to Present ALX148 Clinical Data at the 61st American Society of Hematology Annual Meeting (ASH)


Nov 11, 2019

Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965


Nov 8, 2019

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC



Nov 8, 2019

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC


Nov 4, 2019

Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510


Oct 31, 2019

Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease


Oct 28, 2019

Microbion Corporation Announces Results from Randomized, Double Blind, Placebo-Controlled Phase 1b Trial of Pravibismane (MBN-101) for Treatment of Moderate to Severe Chronic Infected Diabetic Foot Ulcers


Oct 26, 2019

Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences



Oct 25, 2019

LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study


Oct 24, 2019

Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference


Oct 22, 2019

Cerevel Therapeutics Initiates Phase 1b Clinical Trial of CVL-231, a M4 Selective Positive Allosteric Modulator in Development for the Treatment of Schizophrenia


Oct 18, 2019

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies


Oct 17, 2019

Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease



Oct 16, 2019

Amphivena Initiates Solid Tumor Clinical Trial


Oct 16, 2019

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS


Oct 15, 2019

Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019


Oct 15, 2019

Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting 2019


Oct 9, 2019

Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma



Oct 7, 2019

Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease


Oct 2, 2019

Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer's Patients


Oct 1, 2019

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Center


Sep 30, 2019

Tarveda Therapeutics Presents Data from the Phase 1 Portion of a Phase 1/2a Study of PEN-866 at the European Society for Medical Oncology (ESMO) Congress 2019


Sep 30, 2019

MiNA Therapeutics Presents Clinical and Pre-Clinical Data at ESMO Supporting MTL-CEBPA as Immunological Combination Treatment



Sep 30, 2019

Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome


Sep 30, 2019

Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 and 1/2a Clinical Trials USA - English Nederland - Nederlands España - español


Sep 30, 2019

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019


Sep 28, 2019

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor


Sep 28, 2019

Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019



Sep 28, 2019

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor


Sep 26, 2019

Vigeo Therapeutics to Present Results from Its Phase 1 Study Evaluating VT1021 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology (ESMO) 2019 Congress


Sep 23, 2019

Tarveda Therapeutics to Present at Upcoming Conferences


Sep 18, 2019

Versantis Closes CHF 16M Series B Financing Round to Advance Clinical Development of Novel Therapeutics for Liver Diseases


Sep 4, 2019

Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor



Aug 30, 2019

Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors


Aug 30, 2019

Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda in Multiple Solid Tumors


Aug 20, 2019

Forendo Pharma Commences Phase 1b Proof of Mechanism Study with its Lead Endometriosis Program, HSD17B1 Inhibitor FOR-6219


Aug 14, 2019

ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204


Aug 13, 2019

Terns Pharmaceuticals Announces Positive Interim Results From Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH



Aug 8, 2019

Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'


Aug 8, 2019

ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance


Aug 1, 2019

I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors


Jul 23, 2019

Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease


Jul 23, 2019

Immix Receives FDA Authorization to Expand Clinical Trial under US IND



Jul 22, 2019

Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors


Jul 16, 2019

Athira Pharma Presents Preliminary Results from Phase 1 Trial of NDX-1017 at Alzheimer's Association International Conference 2019 (AAIC)


Jul 16, 2019

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative


Jul 8, 2019

Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471


Jun 27, 2019

Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis



Jun 26, 2019

TARIS Announces Positive Results of Phase 1b Trial of TAR-200 in Muscle Invasive Bladder Cancer


Jun 25, 2019

Rodin Therapeutics Announces Positive Phase 1 Results Supporting Continued Development of RDN-929 for Treatment of Neurologic Diseases


Jun 17, 2019

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors


Jun 14, 2019

Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019


Jun 13, 2019

Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of TERN-101



Jun 6, 2019

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-887 for Kidney Disease


Jun 4, 2019

Cellenkos, Inc. Initiates Phase 1 Clinical Trial of CK0801 for Treatment of Bone Marrow Failure Syndromes


Jun 3, 2019

BERG Presents Key Findings From Two Important Clinical Initiatives At The 2019 ASCO Annual Meeting: BERG's Final Phase 1 Results For BPM 31543 In Chemotherapy-Induced Alopecia And A Clinical Study Using BERG's Interrogative Biology® Platform Demonstrating The Importance Of Altruism In Pancreatic Cancer Biomarker Discovery


Jun 3, 2019

Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent Malignant Gliomas


May 31, 2019

Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO



May 30, 2019

Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors


May 24, 2019

Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 and 3 Inhibitor


May 22, 2019

89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH


May 17, 2019

Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting


May 16, 2019

Adastra Pharmaceuticals Announces that Data from Phase 1b Clinical Trial of Zotiraciclib Will Be Presented at ASCO 2019



May 15, 2019

Landos Biopharma Announces Publication of Results from First-in-Human Phase 1 Study of BT-11 in Healthy Volunteers


May 14, 2019

Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors


May 13, 2019

ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer


May 9, 2019

Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma


May 6, 2019

SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors



May 4, 2019

Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease


Apr 30, 2019

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424


Apr 30, 2019

Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'


Apr 24, 2019

Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor


Apr 18, 2019

Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965



Apr 9, 2019

Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis


Apr 3, 2019

Metacrine to Present Phase 1 Results of MET409, an Optimized Next Generation FXR Agonist at The International Liver Congress (EASL) 2019


Apr 1, 2019

BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140


Apr 1, 2019

Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma


Mar 29, 2019

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing



Mar 29, 2019

Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019


Mar 28, 2019

IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427


Mar 7, 2019

Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting


Mar 6, 2019

AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis


Mar 5, 2019

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer



Mar 4, 2019

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor


Mar 4, 2019

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 and 3 Inhibitor


Feb 27, 2019

First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting


Feb 22, 2019

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin


Feb 22, 2019

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin



Feb 20, 2019

Torque Initiates Phase 1 Clinical Trial of TRQ-1501 Deep IL-15 Primed T Cells in Patients with Advanced Solid Tumors or Lymphomas


Feb 19, 2019

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™


Feb 13, 2019

Sojournix Announces Positive Top-Line Phase 1 Data Demonstrating Clinical Proof of Mechanism and Once-Daily (QD) Pharmacokinetics for SJX-653


Feb 6, 2019

Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile


Jan 30, 2019

Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute



Jan 24, 2019

Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression


Jan 24, 2019

Abide Therapeutics Appoints Kevin Finney as President and Chief Operating Officer


Jan 22, 2019

Attune Pharmaceuticals Announces Positive Phase 1 Results for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE


Jan 16, 2019

AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial


Jan 10, 2019

Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-1287 in Phase 1 Study in Patients with Advanced Solid Tumors



Jan 7, 2019

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor


Jan 7, 2019

Landos Biopharma Announces Final Safety Results from Phase 1 Study of BT-11 in Healthy Volunteers


Jan 7, 2019

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 and 3 Inhibitor


Jan 6, 2019

Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia


Jan 4, 2019

Tarveda Therapeutics Provides Year-End Update



Jan 3, 2019

Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809


Jan 3, 2019

Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer


Dec 27, 2018

Bio-Thera Solutions Files IND for Phase 1 Clinical Trial with BAT8003 (Trop2-ADC) as Treatment for Trop2 Positive Cancers


Dec 21, 2018

Viriom to Report Results from Phase 1b Clinical Trial of Once Weekly Oral HIV Treatment


Dec 20, 2018

Viriom Initiates Phase 1 Clinical Trial of Once Monthly Injectable HIV Treatment



Dec 19, 2018

Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes


Dec 18, 2018

Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug


Dec 12, 2018

Rodin Therapeutics Announces Initiation of Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases


Dec 10, 2018

Karuna Pharmaceuticals to Present Results of KarXT Phase 1 Study at American College of Neuropsychopharmacology Annual Meeting


Dec 10, 2018

Immix Observes Clinical Benefit at Dose-Level 2 in Phase 1b Clinical Trial in Refractory Cancer



Dec 6, 2018

Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma


Dec 3, 2018

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting


Dec 3, 2018

Amphivena Presents at ASH First-in-Human Phase 1 Clinical Data on AMV564


Nov 29, 2018

Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting


Nov 27, 2018

Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease



Nov 26, 2018

Forbius’ AVID200, a novel TGF-beta 1 & 3 Inhibitor, Cleared by the FDA to Commence Phase 1 Clinical Trial in Solid Tumors


Nov 26, 2018

Forbius’ AVID200, a novel TGF-beta 1 and 3 Inhibitor, Cleared by the FDA to Commence Phase 1 Clinical Trial in Solid Tumors


Nov 16, 2018

Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism


Nov 12, 2018

NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)


Nov 12, 2018

Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure



Nov 8, 2018

FLX Bio Highlights Phase 1 Data for FLX475 at SITC 2018


Nov 8, 2018

Visterra Initiates Phase 1 Clinical Study of VIS649


Nov 6, 2018

NGM Bio Announces Multiple Presentations at AASLD's The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313


Oct 31, 2018

Rgenix Treats First Patient in Phase 1 Trial of RGX-202


Oct 25, 2018

89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing



Oct 24, 2018

Cortexyme Announces Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer’s Patients


Oct 23, 2018

Context Therapeutics Reports Encouraging Phase 1 Safety and Efficacy Data of Apristor® in Progesterone Receptor Positive Cancers


Oct 23, 2018

IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations


Oct 23, 2018

ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells With N-803, an IL-15 Superagonist


Oct 23, 2018

Apollo Global Management amplia la partnership d’investimento con Apeiron Management



Oct 23, 2018

Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea (paclitaxel micellar)


Oct 23, 2018

RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines


Oct 23, 2018

ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)


Oct 23, 2018

Context Therapeutics Reports Encouraging Phase 1 Safety and Efficacy Data of Apristor in Progesterone Receptor Positive Cancers


Oct 23, 2018

Talaris Therapeutics Adds Two Experienced Biotechnology Executives to its Board of Directors



Oct 22, 2018

amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress


Oct 19, 2018

Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen


Oct 17, 2018

Neurana Pharmaceuticals to Present Tolperisone Phase 1 Clinical Data at the 2018 ACR/ARHP Annual Meeting


Oct 15, 2018

Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia


Oct 10, 2018

Lycera Announces Presentations at the 2018 ESMO Congress for LYC-55716, a First-in-class RORgamma Agonist Candidate



Oct 9, 2018

REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors


Oct 8, 2018

Lyra Therapeutics Presents Clinical Data for LYR-210 for Treatment of Chronic Rhinosinusitis at the American Rhinologic Society Annual Meeting


Sep 27, 2018

Decibel Therapeutics and Oricula Therapeutics Announce Exclusive License for ORC-13661 in Phase 1 Development for Hearing and Balance Protection


Sep 20, 2018

Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure


Sep 17, 2018

Lyra Therapeutics to Present Clinical Data from Phase 1 Study of LYR-210 for the Treatment of Chronic Rhinosinusitis



Sep 5, 2018

Eureka Therapeutics Achieves Regression of Metastatic Liver Cancer Using ET140202 T-cell Therapy


Sep 5, 2018

Kineta Initiates First-in-Human Clinical Trial of LHF-535, a Novel Therapy for Lassa Fever


Sep 5, 2018

MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA


Aug 29, 2018

Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia


Aug 8, 2018

OncoPep Announces a Phase 1b Clinical Trial of Its Multi-Peptide Cancer Vaccine PVX-410 in Combination with Citarinostat for Smoldering Multiple Myeloma



Aug 6, 2018

Applied BioMath, LLC Extends Collaboration into Phase 1 with Northern Biologics for Clinical Pharmacology Support and Semi-Mechanistic PK/PD Modeling Support in Oncology


Jul 30, 2018

Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension, Demonstrating Significant Improvements in Taste and Palatability


Jul 26, 2018

Proclara Biosciences Announces Initiation of NPT189 Clinical Development for Systemic Amyloidoses and Provides Pipeline Update


Jul 26, 2018

CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors


Jul 17, 2018

Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain Inhibitor BLD-2660 for Fibrosis



Jul 12, 2018

Landos Biopharma Initiates Phase 1 Clinical Trial of BT-11, an Oral LANCL2 Agonist for Treatment of IBD


Jun 26, 2018

Istari Oncology Announces New England Journal of Medicine Publication of Phase 1 Trial Results in Patients with Recurrent Glioblastoma Treated with PVSRIPO


Jun 25, 2018

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment


Jun 25, 2018

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis


Jun 25, 2018

ImmunoMolecular Therapeutics’ Scientific Co-founder Presents a Novel Small Molecule Approach to Blocking the Autoimmunity in Type 1 Diabetes



Jun 18, 2018

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions


Jun 13, 2018

Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist


Jun 13, 2018

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis


Jun 6, 2018

BlackThorn Therapeutics Initiates Phase 1 Study of BTRX-335140, an Investigational Kappa Opioid Receptor (KOR) Antagonist


Jun 5, 2018

Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301



Jun 4, 2018

Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting


Jun 4, 2018

Rebiotix Microbiota Restoration Therapy™ Products, Microbiome Health Index™ to Take Center Stage at Digestive Disease Week 2018


Jun 4, 2018

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma


Jun 4, 2018

Ayala Pharmaceuticals Presents Phase 1b Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting for AL101, a Pan-Notch Inhibitor, in Patients with Locally Advanced or Metastatic Solid Tumors


Jun 4, 2018

PIN Pharma Announces Interim Results of Phase 1 Study with PIN-2



Jun 4, 2018

Results from Genelux Corporation's Phase 1b Trial of GL-ONC1 in Recurrent Ovarian Cancer to be presented at the ASCO Annual Meeting 2018


Jun 1, 2018

Enterome to Feature Promising Phase 1 Clinical Data With its Lead Candidate EB8018 for Crohn's Disease at the Digestive Disease Week 2018


May 31, 2018

Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress


May 30, 2018

Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting


May 25, 2018

Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with ThromboGenics



May 24, 2018

Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer


May 24, 2018

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-Based Cancer Specific Immunotherapy (ECI-006) in Melanoma


May 21, 2018

Peloton Therapeutics, Inc. to Present Phase 1 Data Evaluating its Oral HIF-2α Inhibitor PT2977 in Patients with Advanced Solid Tumors at 2018 ASCO Annual Meeting


May 21, 2018

Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting


May 19, 2018

Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting



May 17, 2018

Tarveda Therapeutics to Present Data from Phase 1 Study of PEN-221 at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting


May 14, 2018

Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer


May 14, 2018

Concentric Analgesics Announces Positive Topline Results from Phase 1b Clinical Trial for CA-008 in Post-Surgical Pain


May 11, 2018

Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer


May 1, 2018

Bioniz Therapeutics Announces Positive Phase 1b Clinical Study Results for Investigational Agent BNZ-1



Apr 10, 2018

Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette Syndrome at the American Academy of Neurology 70th Annual Meeting


Apr 5, 2018

Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting


Apr 5, 2018

Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916)


Mar 19, 2018

eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma


Mar 12, 2018

Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883



Mar 12, 2018

Saniona AB: Saniona's partner Cadent Therapeutics initiates Phase 1 trial for joint ataxia and tremor program


Mar 1, 2018

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA™


Feb 22, 2018

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Metastatic Triple Negative Breast Cancer


Feb 14, 2018

Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia


Feb 7, 2018

Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache



Feb 1, 2018

Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-in-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer


Jan 24, 2018

Apexian Pharmaceuticals Opens Phase 1 Clinical Study of APX3330 in Patients with Solid Tumors


Jan 16, 2018

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018


Jan 9, 2018

Rebiotix Highlights 2017 Achievements and 2018 Objectives


Jan 8, 2018

TopiVert Pharma Limited: Positive results from TOP1288 Phase 1 study



Jan 5, 2018

Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Programs


Jan 4, 2018

Cortexyme Initiates Phase 1 Clinical Development of COR388, a Promising Potential Treatment for Alzheimer’s and Other Degenerative Diseases


Jan 4, 2018

Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab


Dec 21, 2017

FLX Bio Completes $60 Million Series C Financing


Dec 20, 2017

Peloton Therapeutics Phase 1 Study of PT2385 Published in the Journal of Clinical Oncology Validates HIF-2α Antagonism for the Treatment of Kidney Cancer



Dec 19, 2017

Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study


Dec 18, 2017

Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma


Dec 18, 2017

Samumed Doses First Patient in Phase 1 Trial of SM04690 for Treatment of Degenerative Disc Disease


Dec 11, 2017

Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors


Dec 6, 2017

MicuRx Announces Closing of ¥100 Million Funding



Nov 30, 2017

Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of its Oral CDK7 Inhibitor: CT7001


Nov 30, 2017

Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease


Nov 30, 2017

Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease


Nov 29, 2017

Rebiotix Announces Expansion of Phase 1 Trial of the Company's Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms


Nov 29, 2017

Apexian Pharmaceuticals is Closing a Series A Round to Initiate Phase 1 Trial



Nov 28, 2017

Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome


Nov 20, 2017

Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders


Nov 15, 2017

PIN Pharma Announces Initiation of its First Phase 1 Study


Nov 10, 2017

IRX Therapeutics Announces Presentation of IRX-2 Phase 1b Biomarker Data in Early Stage Breast Cancer


Nov 6, 2017

Tetra Discovery Partners Research Supports Ability of Novel Selective PDE4D Inhibitor, BPN14770, to Improve Memory and Cognition



Nov 6, 2017

AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma


Nov 3, 2017

Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies


Nov 2, 2017

Bioniz Therapeutics to Present New Data at the 2017 ASH Annual Meeting


Nov 1, 2017

Bexion Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of BXQ-350 in Patients with Advanced Solid Tumors in Collaboration with CTI Clinical Trial and Consulting


Oct 31, 2017

Impel NeuroPharma Announces First Patient Dosed in Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache



Oct 31, 2017

Samumed Initiates Phase 1b Trial of SM04755 for Treatment of Psoriasis


Oct 31, 2017

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients


Oct 27, 2017

ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology


Oct 25, 2017

New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting


Oct 19, 2017

Biscayne Neurotherapeutics Reports Successful Phase 1b Clinical Trial Results For Its Novel Antiepileptic Agent



Oct 17, 2017

Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies


Oct 11, 2017

VLP Therapeutics Announces Phase 1 SBIR Grant Award from National Cancer Institute


Oct 10, 2017

Abide Therapeutics Announces Dosing of First Subject in Phase 1b Study of ABX-1431 in Patients with Neuromyelitis Optica (NMO)


Oct 9, 2017

Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017


Oct 3, 2017

Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Meniere's Disease



Oct 2, 2017

Profectus BioSciences Awarded NIH Contract for up to $22.25 Million to Develop Multi-Component Vaccine for Ebola, Marburg, and Lassa Viruses


Sep 28, 2017

CBT Pharmaceuticals Announces First U.S. Patient Dosed in Phase 1 Clinical Trial of c-Met inhibitor, CBT-101, for Advanced Solid Tumors with c-Met Dysregulation


Sep 26, 2017

Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma


Sep 26, 2017

Centrexion Therapeutics to Present Clinical Data from Pipeline of Chronic Pain Treatments at the 11th Annual Pain and Migraine Therapeutics Summit


Sep 21, 2017

FLX Bio Selects Immuno-Oncology Clinical Candidate



Sep 14, 2017

Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell Disease


Sep 13, 2017

Neuraltus Pharmaceuticals and the University of Hawaii at Manoa Announce Initiation of Phase 1b Study of NP001 in Patients with Mild-to-Moderate Alzheimer's Disease


Sep 11, 2017

Lycera Presents Encouraging Safety Results from Phase 1 ARGON Study of LYC-55716 at the European Society for Medical Oncology (ESMO) Congress


Aug 1, 2017

Amygdala Neurosciences Initiates Phase 1b Clinical Study of ANS-6637, the First-In-Class Selective ALDH2 Inhibitor in Development as a Treatment for Substance Use Disorder


Jul 25, 2017

Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration



Jul 19, 2017

Bioniz Therapeutics Reports Top-Line Phase 1 Clinical Study Results for BNZ-1, A Novel Multi-Cytokine Inhibitor


Jul 17, 2017

Proclara Biosciences Announces Pipeline Progress


Jun 29, 2017

Cytovation Announces Private Fundraising Round of NOK 20m to Progress CyPep-1 to Phase 1 Clinical Study


Jun 20, 2017

Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference


Jun 13, 2017

ENYO Pharma SA Announces Successful Completion of EYP001 First in Man Phase 1 Study



Jun 7, 2017

Eureka Therapeutics and City of Hope Announce Agreement to Conduct Phase 1 Clinical Trial of Investigational ET1402L1 CAR-T Therapy in Liver Cancer


Jun 5, 2017

eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017


May 24, 2017

ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers


May 23, 2017

United Neuroscience Reports Positive Phase 1 Results for Active Vaccine UB-311 in Alzheimer’s Disease


May 15, 2017

Longeveron Announces Publication of Phase 1 Safety and Efficacy Trial Results for Allogeneic Stem Cell Treatment in Frailty Patients



May 10, 2017

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma


May 10, 2017

Longeveron Begins Enrollment of Second Cohort of Phase 1 Trial of Allogeneic Mesenchymal Stem Cells to Treat Alzheimer's Disease Patients


May 4, 2017

Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery


May 1, 2017

Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors


Apr 27, 2017

Amazentis SA Announces Successful Phase 1A/1B Study Results in Healthy Elderly Subjects with the Food Metabolite Urolithin A



Apr 18, 2017

Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America


Apr 4, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017


Mar 30, 2017

Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma


Mar 1, 2017

OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial


Feb 23, 2017

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium



Feb 22, 2017

ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 for the Treatment of Celiac Disease


Feb 16, 2017

Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery


Feb 6, 2017

Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017


Feb 2, 2017

Tarveda Therapeutics Raises $30 Million in Series D Financing to Advance Pentarin Miniaturized Drug Conjugates


Jan 27, 2017

Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing



Jan 11, 2017

Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material, and Enters into a Collaboration and Option Agreement with Janssen Pharmaceuticals, Inc.


Jan 9, 2017

Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds


Jan 6, 2017

CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor


Jan 6, 2017

Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic


Jan 4, 2017

Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection



Jan 4, 2017

Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors


Jan 4, 2017

Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN003, a Novel and Highly Selective B-RAF/PI3 Kinase Inhibitor


Jan 2, 2017

Ensysce Biosciences to present initial Phase 1 data on abuse deterrent opioid, PF614, at Biotech Showcase™ 2017.


Dec 19, 2016

Poxel Announces Phase 1 Initiation of EYP001 for the Treatment of Chronic Hepatitis B Virus Infection by Licensing Partner ENYO Pharma SA


Dec 16, 2016

ENYO Pharma SA Announces Successful Initiation of the Phase 1 Clinical Programme with EYP001, Its Lead Candidate for the Treatment of Chronic Hepatitis B Virus Infection



Dec 14, 2016

Abide Therapeutics Announces First Patient Dosed in Phase 1b Study to Assess the Effect of ABX-1431 in Patients with Functional Dyspepsia


Dec 1, 2016

Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial to Study PF614, BIO-MD™ Prodrug of Oxycodone


Nov 30, 2016

MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4


Nov 28, 2016

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Triple Negative Breast Cancer


Nov 28, 2016

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Smoldering Multiple Myeloma and Upcoming Presentation of Positive Results from Phase 1/2a Clinical Trial at ASH



Nov 18, 2016

Triphase Accelerator Corporation Announces Full Enrollment Results of Its Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma


Nov 16, 2016

Imara Announces First Subject Dosed in Phase 1 Study of Lead Product Candidate, IMR-687


Nov 11, 2016

Cognition Therapeutics Announces Dosing of First Alzheimer's Patient in Phase 1b Trial of CT1812


Oct 28, 2016

Celtaxsys Announces Publication of Results Demonstrating the Safety, Tolerability and Optimal PK/PD Profile of First-In-Class Anti-Inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials Including Cystic Fibrosis Patients


Oct 27, 2016

Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab



Sep 12, 2016

Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections


Sep 8, 2016

Avelas Biosciences Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial


Sep 7, 2016

Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease


Aug 23, 2016

Spyryx Biosciences Expands Executive Team, Appoints Pulmonary Industry Leader, Alistair Wheeler, MD, MFPM as Chief Medical Officer


Aug 10, 2016

TARIS Biomedical Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Bladder Cancer



Aug 1, 2016

Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors


Jul 25, 2016

Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer's Patients with APOE4/4 Homozygous Genotype


Jul 13, 2016

TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer


Jul 13, 2016

TARIS Biomedical Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer


Jun 8, 2016

NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH



Jun 4, 2016

Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma


May 24, 2016

ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease


May 20, 2016

Checkmate Pharmaceuticals Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer and Announces Dosing of First Patient in Immuno-Oncology Phase 1b Trial with CMP-001, a TLR9 Agonist


May 9, 2016

Avelas Biosciences Announces Positive Interim Phase 1b Results and Advances to Dose Expansion Stage


May 2, 2016

SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer



Apr 19, 2016

Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma


Apr 1, 2016

Tetra Discovery Advances Alzheimer's Treatment Candidate BPN14770 to Phase I Multiple Ascending Dose Trial


Feb 26, 2016

Visterra Announces Publication of Clinical Data on VIS410 in the Journal EBioMedicine


Jan 19, 2016

Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial


Jan 12, 2016

FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies



Jan 6, 2016

Embera NeuroTherapeutics Announces Successful Completion of Phase 1 Clinical Trial Testing EMB-001, a Potential Novel Treatment for Addictions


Dec 9, 2015

Tetra Discovery Initiates Phase 1 Study of BPN14770, Under Development for Treatment and Prevention of Alzheimer's Disease


Dec 8, 2015

Panacea Pharmaceuticals closes its Series E financing for a total of $15 million to fund the Phase 1 clinical study of its lead cancer immunotherapeutic drug and pursue its late stage pre-clinical candidates toward integrated cancer management


Nov 6, 2015

Alzheon Announces Initiation of Clinical Studies with ALZ-801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease


Sep 22, 2015

Blaze Bioscience Commences Clinical Trial of BLZ-100 in Patients with Sarcoma Undergoing Surgery



Sep 16, 2015

EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients


Aug 31, 2015

FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925


Aug 19, 2015

EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors


Aug 12, 2015

Neuropore Therapies Commences Phase 1 Clinical Trials


Jul 27, 2015

Aspyrian Therapeutics Inc. Closes $4.25M Series A Extension Financing to Support the Execution of Phase 1 Clinical Studies of the Precision Targeted Cancer Therapy, RM-1929, to Treat Late-Stage Recurrent Head and Neck Cancers



Jul 8, 2015

AXON Neuroscience’s Vaccine to Halt Alzheimer’s Finishes Phase 1 Clinical Trial


Jun 16, 2015

Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M


Jun 15, 2015

EnGeneIC and Asbestos Diseases Research Institute Announce Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients


Jun 15, 2015

Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis


Jun 4, 2015

Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Children with Brain Cancer



May 28, 2015

Cavion to Present Clinical Trial Data at ASCO


Apr 30, 2015

Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease


Apr 16, 2015

Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients


Mar 20, 2015

Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease


Mar 10, 2015

PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapies, AGT-182 and AGT-181, for Phase 1 Clinical Trial



Feb 25, 2015

MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I


Feb 18, 2015

ReveraGen BioPharma Announces Start Of Phase 1 Clinical Trial Of VBP15 Dissociative Steroid Drug


Jan 8, 2015

Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Advanced Solid Tumors


Dec 15, 2014

Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury


Dec 3, 2014

Rhizen Pharmaceuticals S.A. to present Phase 1 clinical and additional preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in hematological malignancies



Nov 10, 2014

EnGeneIC and Asbestos Diseases Research Institute Initiate MesomiR-1 Phase 1 Trial in Patients with Late Stage Mesothelioma


Nov 3, 2014

QUE Oncology, Inc. Announces Positive Phase 1 Results with Q-122


Oct 31, 2014

Xcovery Presents Phase 1 Results of X-396 in ALK positive NSCLC at the 2014 Multidisciplinary Symposium in Thoracic Oncology


Oct 31, 2014

Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax™-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses


Oct 29, 2014

Xcovery Raises $20M through Equity Investment from China’s Betta Pharmaceuticals for Development of ALK Inhibitor



Oct 7, 2014

Cavion and Yale University Announce First Patient Enrolled in Phase 1b Clinical Trial in Brain Cancer


Sep 4, 2014

Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Multiple Myeloma


Jun 20, 2014

Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug


Jun 3, 2014

Xcovery Presents Interim Phase 1 Results of X-396 in ALK positive NSCLC at the American Society for Clinical Oncology Annual Meeting


May 15, 2014

PanOptica Raises $45 Million to Finance Clinical Development of Anti-VEGF Eye Drop for Wet AMD



Dec 19, 2013

MicuRx Expands Global Clinical Trial Program For Oral Antibiotic MRX-I


Dec 19, 2013

Blaze Bioscience Announces Initiation of First-in-Human Phase 1 Clinical Study of BLZ-100


Dec 4, 2013

3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors


Oct 28, 2013

Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017


Oct 3, 2013

Prolong Pharmaceuticals Presents Phase 1 Results For Flagship Product SANGUINATE™



Sep 17, 2013

Profectus BioSciences Announces Initiation of Clinical Trial Evaluating its Therapeutic HIV Vaccine in Support of the “Cure Agenda”


Sep 11, 2013

Theraclone Sciences Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013


Aug 22, 2013

C3 Jian Successfully Completes Phase 1 Clinical Trial for Dental Caries Product


May 6, 2013

Trevi Therapeutics Commences Clinical Study of Nalbuphine ER


May 2, 2013

Theraclone Sciences Announces Positive Top-line Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection



Feb 19, 2013

C3 Jian Completes C16G2 Phase 1 Clinical Study Enrollment


Jan 3, 2013

Celtaxsys Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary Inflammation


Dec 4, 2012

Profectus BioSciences’ Vesicular Stomatitis Virus-Vectored HIV-1 Vaccine Safe and Immunogenic in Government Sponsored Phase 1 Trial


Nov 8, 2012

Iconic Therapeutics Announces Phase 1 Wet AMD Study Results


Sep 10, 2012

Theraclone Sciences Presents Phase 1 Results of TCN-032, its Therapeutic Antibody Directed at Influenza A, at ICAAC 2012



Sep 5, 2012

Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study


Aug 7, 2012

Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1


Jun 14, 2012

Theraclone Sciences Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus Infection


May 15, 2012

Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza A


Apr 23, 2012

MicuRx Pharmaceuticals Completes Phase 1 Trial For MRX-I, A Next-Generation Antibiotic



Mar 7, 2012

Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)


Sep 21, 2011

Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A


Aug 15, 2011

Embera NeuroTherapeutics Closes on $4.5 Million Continuation of Series A Financing


Jun 14, 2011

Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)


May 12, 2011

Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacterial Infections and Sepsis.



May 9, 2011

ImmusanT Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease


Apr 20, 2011

Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam


Jan 5, 2011

Profectus BioSciences Announces Initiation of Clinical Trial of IL-12 Enhanced Therapeutic HIV DNA Vaccine Delivered Using Electroporation


Dec 9, 2010

Argos Therapeutics' Arcelis™ HIV Immunotherapy Shows Feasibility to Generate Fully Functional Dendritic Cells From Viremic Patients


Dec 7, 2010

Argos Therapeutics Initiates Dosing of Patients in Phase 1 Clinical Trial of Monoclonal Antibody-Based Therapy for Treatment of Systemic Lupus Erythematosus



Nov 30, 2010

Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1 NP001 Study in the Treatment of Amyotrophic Lateral Sclerosis (ALS)


Sep 14, 2010

Atox Bio Announces Dosing of the First Subject in Its Phase 1 Study of AB103


Dec 2, 2009

TARIS Successfully Completes Phase 1 Study


Jul 23, 2009

Promedior Initiates Phase 1 Clinical Trial of PRM-151, a Novel Compound for the Treatment of Fibrotic Diseases and Tissue Remodeling


Mar 18, 2009

Numerate Awarded Phase 1 NIH Grant to Support Design of New Therapies for Celiac Disease



Mar 12, 2007

Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation